Open house drug discount agreements Octreotide, ATC H01CB02
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Octreotid, ATC H01CB02
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Non-exclusivity and open entry may lead to many competitors, reducing per-company share
Automatic termination if other discount agreements (bundesweit or landesspezifisch) come into effect
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2027
- Enter into non-exclusive discount agreements for Octreotide (ATC H01CB02) with all eligible pharmaceutical companies
Show full summary
Open-house model by AOK Bayern for non-exclusive discount agreements for Octreotide (ATC H01CB02). All eligible pharmaceutical companies can join by submitting signed documents. No competitive selection. Contracts run from 01.11.2025 to 31.10.2027 with rolling enrollment until 03.09.2027.
Risks
Non-exclusivity and open entry may lead to many competitors, reducing per-company share
Automatic termination if other discount agreements (bundesweit or landesspezifisch) come into effect
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company
Administrative
- Submit signed declaration of reliability
- Submit signed contract with annex listing drugs
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house drug discount agreements Octreotide, ATC H01CB02
Non-exclusive discount agreements for Octreotide (ATC H01CB02) under §130a Abs. 8 SGB V. All eligible pharmaceutical companies can participate. No selection.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Octreotid, ATC H01CB02
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Sep 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 600472-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Non-exclusivity and open entry may lead to many competitors, reducing per-company share
Automatic termination if other discount agreements (bundesweit or landesspezifisch) come into effect
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications